Original Source(s)
Related Content
Does TYK2/JAK1 Show Potential in Inflammatory Diseases?
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.
July 6, 2026
-
3 min
FDA Expands Test for Gastric and Esophageal Cancers
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
-
2 min
Top 10 CDC Updates Physicians Should Know
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
July 9, 2026
-
6 min